Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02523014 · ClinicalTrials.gov registry record · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
A Phase 2 study of Recurrent Meningioma and Intracranial Meningioma, sponsored by Alliance for Clinical Trials in Oncology.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT02523014: Recruiting Phase 2 study of Recurrent Meningioma and Intracranial Meningioma, sponsored by Alliance for Clinical Trials in Oncology.
NCT02523014 is a Phase 2 study of Recurrent Meningioma and Intracranial Meningioma that is actively recruiting participants, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 124 participants, above the 33-participant average among 6 other Recurrent Meningioma trials with a reported enrollment target (276% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02523014, a Phase 2 study of Recurrent Meningioma and Intracranial Meningioma, is actively recruiting participants, sponsored by Alliance for Clinical Trials in Oncology.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Point estimates and 95% binomial confidence intervals will be generated for the six month PFS rate within each cohort of each treatment arm. Kaplan-Meier curves will be generated for PFS for each cohort within each treatment arm.
Conditions Studied
Interventions
- DRUG Abemaciclib
- DRUG Vismodegib
- DRUG Capivasertib
- DRUG FAK Inhibitor GSK2256098
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
Arizona
- Kingman Regional Medical Center - Kingman
- Cancer Center at Saint Joseph's - Phoenix
- Saint Joseph's Hospital and Medical Center - Phoenix
- Mayo Clinic in Arizona - Scottsdale
- Arizona Oncology Services Foundation - Scottsdale
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
- CARTI Cancer Center - Little Rock
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- PCR Oncology - Arroyo Grande
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2015-09-28 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
What NCT02523014 shows while recruiting
NCT02523014 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, above the 33-participant average among 6 other Recurrent Meningioma trials with a reported enrollment target (276% higher).
The record links to 3 conditions, with Recurrent Meningioma appearing as the primary indexed condition, and to 4 interventions - of which Abemaciclib is the first listed.
NCT02523014 names 20 study sites across 5 states, led by Alaska, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT02523014 about?
NCT02523014 is a clinical study titled "Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas". This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the g...
What is the current status of trial NCT02523014?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2015-09-28. Estimated completion is 2028-01.
What conditions does trial NCT02523014 study?
This clinical trial studies the following conditions: Recurrent Meningioma, Intracranial Meningioma, NF2 Gene Mutation.
What interventions are being tested in trial NCT02523014?
The interventions under investigation include: Abemaciclib (DRUG), Vismodegib (DRUG), Capivasertib (DRUG), FAK Inhibitor GSK2256098 (DRUG).
Who is sponsoring clinical trial NCT02523014?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02523014 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
RECRUITING · Phase 2
-
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
RECRUITING · Phase 2
-
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
RECRUITING · Phase 2
-
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
RECRUITING · NA
-
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
RECRUITING · Phase 1
-
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
- NCT04959695 · 124 participants · NA
Evaluation of the PE Coach Mobile Application Among Veterans With PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI